Headache News and Research

Latest Headache News and Research

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Afghanistan's geography is dominated by a collection of craggy peaks, the highest-a mountain known as Noshaq-has been measured to 7,492 meters. Consequently, the soldiers on duty in this mountainous terrain must often ascend to great heights as part of their duty.

22 Apr 2013

3-D brain images provide a better understanding on migraine attack

Wielding a joystick and wearing special glasses, pain researcher Alexandre DaSilva rotates and slices apart a large, colorful, 3-D brain floating in space before him.

22 Apr 2013

New review of medications to prevent migraines appears in Journal of General Internal Medicine

Migraine headaches are a major cause of ill health and a reduced quality of life. Some individuals suffer from a frequent and severe migraine problem which means that they require regular medication to try and prevent them.

18 Apr 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

Acetaminophen may help reduce existential pain

Thinking about death can cause us to feel a sort of existential angst that isn't attributable to a specific source. Now, new research suggests that acetaminophen, an over-the-counter pain medication, may help to reduce this existential pain.

17 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Migraine affects an estimated 30 million people in the U.S, with the one year prevalence of migraine estimated at 12% of the general population, including 18% of all women and 6% of all men.

12 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Viewpoints: Obama budget doesn't address 'heart of our debt crisis;' Attention deficit crisis; Insurer sings a different song when consumer owes it money

The U.S. has huge budget challenges. And for the first time in years, we will have three budget proposals to carefully consider -- instead of speeches and talking points.

11 Apr 2013

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.

9 Apr 2013

Migraine sufferers should undergo more formal experiments, says study

Women often point to stress, hormones, alcohol, or even the weather as possible triggers for their migraines. But a new study from Wake Forest Baptist Medical Center found that it is nearly impossible for patients to determine the true cause of their migraine episodes without undergoing formal experiments.

8 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders.

4 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

Headache News and Research

Latest Headache News and Research

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

3-D brain images provide a better understanding on migraine attack

New review of medications to prevent migraines appears in Journal of General Internal Medicine

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

Acetaminophen may help reduce existential pain

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Viewpoints: Obama budget doesn't address 'heart of our debt crisis;' Attention deficit crisis; Insurer sings a different song when consumer owes it money

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Migraine sufferers should undergo more formal experiments, says study

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

Clinical trial signals new era in treatment of neurodegererative disorders

Revance Therapeutics raises $33M in Series E financing

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in